Graph Therapeutics vs Sightera Biosciences
Graph Therapeutics vs Sightera Biosciences, compared side by side on 14 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Graph Therapeutics is on 44/100 and Sightera Biosciences on 43/100.
Where each one leads
Graph Therapeutics
- funding raised: $5.0M against $3.0M
Sightera Biosciences
- agent readiness: 47/100 against 41/100
At a glance
| Measure | Graph Therapeutics | Sightera Biosciences |
|---|---|---|
| What it is | Developing precision medicines for inflammatory and immune-mediated diseases using AI and patient sample analysis. | AI drug discovery startup that learns directly from patient biology to identify and design novel medicines, focusing on oncology and fibrosis. |
| Category | Biotechnology, Artificial Intelligence, Healthcare, Drug Discovery | Biotechnology, Artificial Intelligence, Drug Discovery, Oncology |
| Sells toBusiness model | B2B | B2B |
| Offering | Platform | Platform |
| Founded | 2021 | 2025 |
| Headquarters | Boston, Austria | Antwerp, Belgium |
| Status | Active | Inactive |
Size, funding and growth
| Measure | Graph Therapeutics | Sightera Biosciences |
|---|---|---|
| Total funding | $5.0M | $3.0M |
| Latest round | Funding Round | Pre-Seed |
| LinkedIn followers | 2,302 | Not published |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Graph Therapeutics | Sightera Biosciences |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 44/100 | 43/100 |
| Traction | 33/100 | 32/100 |
| Team | Not published | 60/100 |
| Search visibility | 42/100 | 16/100 |
| Quality | 58/100 | 48/100 |
| Agent readinessHow well an AI agent can read and act on the site | D (41/100) | D (47/100) |
| Domain ratingLink authority, 0-100 | 27/100 | Not published |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Graph Therapeutics | Sightera Biosciences |
|---|---|---|
| CMS | Framer | Not detected |
Graph Therapeutics vs Sightera Biosciences: common questions
Which is better, Graph Therapeutics or Sightera Biosciences?
On our 0-100 score Graph Therapeutics rates higher (44/100 against 43/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 14 data points above: read the rows that match what you are buying for.
How do Graph Therapeutics and Sightera Biosciences compare on the numbers?
Graph Therapeutics leads on funding raised ($5.0M against $3.0M). Sightera Biosciences leads on agent readiness (47/100 against 41/100).
Read the full Graph Therapeutics review and pricing or the Sightera Biosciences review and pricing. You can also browse other Graph Therapeutics alternatives we track.